Aganepag isopropyl

DB16085InvestigationalSmall molecule

Aganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension).

Mechanism: Pharmacologically active on Prostaglandin E2 receptor EP2 subtype
Curator reviewed
Formula / weight: C₂₇H₃₇NO₄S · 471.66 g/mol (avg)
Code names: AGN-210961

Resolves to

Compound

UNIIR096XE6760CAS910562-20-8ChEMBLCHEMBL2105714

Structure

InChIKeyGKRBCKDGBDUAIQ-URXFXBBRSA-NSMILESCCCCC[C@H](O)C1=CC=C(C=C1)N1[C@@H](CCCC2=CC=C(S2)C(=O)OC(C)C)CCC1=O

Targets

P43116PTGER2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Aganepag isopropyl, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account